Back to search

Article

Novel ACE2 nanoparticles universally block SARS-CoV-2 variants in the human respiratory tract

2022-05-06

Abstract excerpt

The continual evolution of SARS-CoV-2 has challenged the efficacy of many COVID19 vaccines and treatment options. One strategy that evades viral escape is using the entry receptor, human Angiotensin-Converting Enzyme 2 (hACE2). Soluble hACE2 receptor domains show potential as decoys but genetic modifications are necessary to provide sufficient efficacy. However, these engineered constructs are potentially suscepti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bdac18a9-4c40-5821-aa14-3d4b9d1c939d
DOI
10.1101/2022.05.05.490805
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Novel ACE2 nanoparticles universally block SARS-CoV-2 variants in the human respiratory tractDOI 10.1101/2022.05.05.490805
Select a neighboring publication to make it the new centre.